Atea Pharmaceuticals AVIR
NASDAQ AVIR
$4.05 -0.03 (-0.74%)
At close: Oct 22, 2026 · 4:00 PM EDT

Atea Pharmaceuticals (AVIR) EBITDA Margin (2021)

Updated

Atea Pharmaceuticals (AVIR) reported EBITDA Margin of 63.06% for Q4 2021, up 130.54 percentage points from the prior quarter.

Analysis

Atea Pharmaceuticals (AVIR) EBITDA Margin (2021) Analysis & Trends

For FY2021, Atea Pharmaceuticals posted EBITDA Margin of 39.39%, up 62.03 percentage points from FY2020.

  • By year, EBITDA Margin came in at -22.64% in FY2020.
  • Per Business Quant data, the three quarters before Q4 2021 came in at -67.48% (Q3 2021), 14.40% (Q2 2021) and 46.47% (Q1 2021).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 32.68%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 49.01%
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 6.02%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 33.11%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 46.01%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -124.26%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 39.16%
10 Atea Pharmaceuticals 325.17 Mn -781.44 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 63.06%
Sep 30, 2021 -67.48%
Jun 30, 2021 14.40%
Mar 31, 2021 46.47%
API Access

Atea Pharmaceuticals EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=AVIR&period=max&api_key=YOUR_API_KEY